These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 16296797)

  • 81. [Modern contraceptive substances, their use and complications].
    Kuprsanin M
    Med Pregl; 1978; 31(11-12):517-9. PubMed ID: 739966
    [No Abstract]   [Full Text] [Related]  

  • 82. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide.
    Woolfson AD; Malcolm RK; Morrow RJ; Toner CF; McCullagh SD
    Int J Pharm; 2006 Nov; 325(1-2):82-9. PubMed ID: 16884869
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Notifications to the Netherlands Pharmacovigilance Foundation Lareb of the expulsion of a vaginal contraceptive ring (NuvaRing) and of pregnancy during the use of it].
    Passier JL; van Puijenbroek EP; van Grootheest AC
    Ned Tijdschr Geneeskd; 2004 Oct; 148(41):2033-5. PubMed ID: 15554002
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Hormonal contraceptive regimens in the perimenopause.
    Hardman SM; Gebbie AE
    Maturitas; 2009 Jul; 63(3):204-12. PubMed ID: 19524378
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Inadvertent vesicular placement of a vaginal contraceptive ring presenting as persistent cystitis.
    Teal SB; Craven WM
    Obstet Gynecol; 2006 Feb; 107(2 Pt 2):470-2. PubMed ID: 16449153
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The contraceptive patch in relation to ischemic stroke and acute myocardial infarction.
    Jick SS; Jick H
    Pharmacotherapy; 2007 Feb; 27(2):218-20. PubMed ID: 17253912
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Single monthly injection for contraception].
    Artner J; Friedrich F
    Geburtshilfe Frauenheilkd; 1970 Jun; 30(6):554-64. PubMed ID: 5475938
    [No Abstract]   [Full Text] [Related]  

  • 88. INFLUENCE OF TWO NONSTEROIDAL ANTIESTROGENS ON VAGINAL OPENING AND PMS-INDUCED OVULATION IN RATS.
    COPPOLA JA; PERRINE JW
    Endocrinology; 1965 May; 76():865-9. PubMed ID: 14290146
    [No Abstract]   [Full Text] [Related]  

  • 89. [Advantages and disadvantages of hormonal pregnancy regulation (so-called ovulation inhibitors)].
    Hauser GA
    Ther Umsch; 1968 Jun; 25(6):332-7. PubMed ID: 5733262
    [No Abstract]   [Full Text] [Related]  

  • 90. Contraception and pregnancy then and now: examining the experiences of a cohort of mid-age Australian women.
    Read C; Bateson D; Weisberg E; Estoesta J
    Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):429-33. PubMed ID: 19694702
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Advances in the control of fertility].
    Vojta M
    Cesk Gynekol; 1970; 35(5):288-9. PubMed ID: 5424915
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Evaluation of contraceptive activity of a mineralo-herbal preparation in Sprague-Dawley rats.
    Srivastava SR; Kesarwani S; Keshri G; Singh MM
    Contraception; 2005 Dec; 72(6):454-8. PubMed ID: 16307970
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Steroid release from polymer vaginal devices. Effect on fertility inhibition.
    Zañartu J; Guerrero R
    Steroids; 1973 Mar; 21(3):325-33. PubMed ID: 4693729
    [No Abstract]   [Full Text] [Related]  

  • 94. Vaginal safety after use of a bioadhesive, acid-buffering, microbicidal contraceptive gel (ACIDFORM) and a 2% nonoxynol-9 product.
    Amaral E; Perdigao A; Souza MH; Mauck C; Waller D; Zaneveld L; Faundes A
    Contraception; 2006 May; 73(5):542-7. PubMed ID: 16627043
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The transdermal patch and the vaginal ring: two novel methods of combined hormonal contraception.
    Swica Y
    Obstet Gynecol Clin North Am; 2007 Mar; 34(1):31-42, viii. PubMed ID: 17472863
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
    Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
    Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [New contraceptive agent: various questions on p-sponges].
    Börjeson CO
    Jordemodern; 1985 Oct; 98(10):326-9. PubMed ID: 3000996
    [No Abstract]   [Full Text] [Related]  

  • 98. Medical eligibility criteria for new contraceptive methods: combined hormonal patch, combined hormonal vaginal ring and the etonogestrel implant.
    Gaffield ME; Curtis KM; Mohllajee AP; Peterson HB
    Contraception; 2006 Feb; 73(2):134-44. PubMed ID: 16413844
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The contraceptive vaginal ring: female adolescents' knowledge, attitudes and plans for use.
    Carey AS; Chiappetta L; Tremont K; Murray PJ; Gold MA
    Contraception; 2007 Dec; 76(6):444-50. PubMed ID: 18061702
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Current studies in contraception: the use of a long-acting progestogen by injection.
    Tyler ET
    S Afr Med J; 1968 Mar; 42(11):257-9. PubMed ID: 4869601
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.